Abstract

Extracellular vesicles (EVs) are lipid-membrane enclosed structures that are associated with several diseases, including those of genitourinary tract. Urine contains EVs derived from urinary tract cells. Owing to its non-invasive collection, urine represents a promising source of biomarkers for genitourinary disorders, including cancer. The most used method for urinary EVs separation is differential ultracentrifugation (UC), but current protocols lead to a significant loss of EVs hampering its efficiency. Moreover, UC protocols are labor-intensive, further limiting clinical application. Herein, we sought to optimize an UC protocol, reducing the time spent and improving small EVs (SEVs) yield. By testing different ultracentrifugation times at 200,000g to pellet SEVs, we found that 48 min and 60 min enabled increased SEVs recovery compared to 25 min. A step for pelleting large EVs (LEVs) was also evaluated and compared with filtering of the urine supernatant. We found that urine supernatant filtering resulted in a 1.7-fold increase on SEVs recovery, whereas washing steps resulted in a 0.5 fold-decrease on SEVs yield. Globally, the optimized UC protocol was shown to be more time efficient, recovering higher numbers of SEVs than Exoquick-TC (EXO). Furthermore, the optimized UC protocol preserved RNA quality and quantity, while reducing SEVs separation time.

Details

Title
Improved recovery of urinary small extracellular vesicles by differential ultracentrifugation
Author
Teixeira-Marques, Ana 1 ; Monteiro-Reis, Sara 2 ; Montezuma, Diana 3 ; Lourenço, Catarina 4 ; Oliveira, Miguel Carlos 1 ; Constâncio, Vera 5 ; Sequeira, José Pedro 6 ; Carvalho-Maia, Carina 7 ; Freitas, Rui 8 ; Martens-Uzunova, Elena S. 9   VIAFID ORCID Logo  ; Vasconcelos, M. Helena 10 ; Henrique, Rui 11   VIAFID ORCID Logo  ; Jerónimo, Carmen 12   VIAFID ORCID Logo 

 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, INEGI-LAETA, Faculty of Engineering, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); IMP Diagnostics, Praça do Bom Sucesso, Porto, Portugal (GRID:grid.435544.7); ICBAS-School of Medicine and Biomedical Sciences-University of Porto, Doctoral Programme in Medical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Universidade do Porto, i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto, Doctoral Programme in Biomedical Sciences, ICBAS-School Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPO Porto), Department of Pathology, Porto, Portugal (GRID:grid.435544.7) 
 Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPOPorto), Department of Urology, Porto, Portugal (GRID:grid.418711.a) (ISNI:0000 0004 0631 0608) 
 University Medical Center Rotterdam, Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.508717.c) (ISNI:0000 0004 0637 3764) 
10  Universidade do Porto, i3S-Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Department of Biological Sciences, FFUP-Faculty of Pharmacy, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
11  Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); Portuguese Oncology Institute of Porto (IPO Porto), Department of Pathology, Porto, Portugal (GRID:grid.435544.7); University of Porto (ICBAS-UP), Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
12  Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Porto, Portugal (GRID:grid.435544.7); University of Porto (ICBAS-UP), Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226) 
Pages
12267
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3060940202
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.